***Test is NOT available for Outreach clients, (but is available to MMC - Dickinson).***
Humira, Amgevita, Hyrimoz, Idacio, Imraldi, Yuflyma
To measure and monitor serum adalimumab (ADA) and antibodies-to-adalimumab (ATA) levels at any time during therapy.
Send ambient or cold pack. Do not freeze.
Frozen Specimens
Whole Blood
This test was developed and its performance characteristics determined by Prometheus Laboratories, CAP-accredited (6805501) and CLIA-certified (05D0917432) as qualified to perform high complexity testing. It has not been cleared or approved by the US Food and Drug Administration
The Anser® ADA test is a quantitative therapeutic drug monitoring (TDM) assay that allows healthcare providers to measure and monitor serum adalimumab (ADA) and antibodies-to-adalimumab (ATA) levels at any time during therapy.
Serum concentrations of adalimumab (ADA) may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of ADA have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to ADA by producing ATA. The presence of ATA has also been associated with higher drug clearance and lower response rates. Therefore, the quantitative measurement of ADA and ATA levels in serum provides valuable information to healthcare providers to better assess a patient's risk or reason for losing response to ADA and helps them decide an appropriate course of action.
Serum adalimumab (ADA) Lower Limit of Quantification: < 1.6 ug/mL
Antibody to adalimumab (ADA) Lower Limit of Quantification: < 1.7 U/mL